Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 November 2012Website:
http://www.travere.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 44 min agoDividend
Analysts recommendations
Institutional Ownership
TVTX Latest News
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in November:
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JPMorgan Greg Wiesner - TD Cowen Joe Thomas - Scotiabank Laura Chico - Wedbush Securities Sadia Rahman - Wells Fargo Operator Good morning, and welcome to the Travere Therapeutics' Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded.
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.17 per share a year ago.
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and efficacy data of FILSPARI in combination treatment in IgAN Late-breaking presentation demonstrates sparsentan delivered rapid and sustained proteinuria reduction, and long-term kidney health benefits in a subset of patients with genetic, often treatment resistant, FSGS SAN DIEGO, Oct. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX), presented new data further demonstrating the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforcing its potential in focal segmental glomerulosclerosis (FSGS) at the American Society of Nephrology (ASN) Kidney Week 2024. “The data presented at ASN provided additional evidence that FILSPARI is effective across all subgroups of IgAN patients studied to-date, and that it achieved significant levels of complete remission when used in newly diagnosed patients.
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET.
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
What type of business is Travere Therapeutics?
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
What sector is Travere Therapeutics in?
Travere Therapeutics is in the Healthcare sector
What industry is Travere Therapeutics in?
Travere Therapeutics is in the Biotechnology industry
What country is Travere Therapeutics from?
Travere Therapeutics is headquartered in United States
When did Travere Therapeutics go public?
Travere Therapeutics initial public offering (IPO) was on 08 November 2012
What is Travere Therapeutics website?
https://www.travere.com
Is Travere Therapeutics in the S&P 500?
No, Travere Therapeutics is not included in the S&P 500 index
Is Travere Therapeutics in the NASDAQ 100?
No, Travere Therapeutics is not included in the NASDAQ 100 index
Is Travere Therapeutics in the Dow Jones?
No, Travere Therapeutics is not included in the Dow Jones index
When was Travere Therapeutics the previous earnings report?
No data
When does Travere Therapeutics earnings report?
Next earnings report date is not announced yet